Beta test rollout. This site is in community QA — please send feature requests, bug reports and data corrections on the Feedback page or on GitHub.

Home
    Disclaimer
    Tfmpp molecular structure

    Tfmpp Stats & Data

    PubChem
    MW230.23
    FormulaC11H13F3N2
    LogP2.3
    IUPAC1-[3-(trifluoromethyl)phenyl]piperazine
    InChIKeyKKIMDKMETPPURN-UHFFFAOYSA-N
    Chemical Class Phenylpiperazine
    Psychoactive Class Stimulant

    Pharmacology

    DrugBank

    Metabolism

    1-(3-Trifluoromethylphenyl)piperazine has known human metabolites that include HO-TFMPP.

    Measured Affinities

    Guide to PHARMACOLOGY

    Measured binding and functional data for TFMPP, curated by the IUPHAR/BPS Guide to PHARMACOLOGY. Each row cites the paper it came from. Lower concentrations mean tighter binding — a value in the sub-nanomolar range indicates a very potent interaction.

    Target Action Measure Value Concentration Species Source
    5-HT2A receptor HTR2A Full agonist pKi 7.5 31.62 nM Human PMID 15322733
    5-HT2B receptor HTR2B Full agonist pKi 7.2 63.1 nM Human PMID 15322733
    5-HT2B receptor Htr2b Full agonist pKi 7.1 79.43 nM Rat PMID 8450835
    5-HT6 receptor HTR6 Full agonist pKi 6.4 398.11 nM Human PMID 8522988
    5-HT6 receptor Htr6 Full agonist pKi 6.3 501.19 nM Rat PMID 7680751
    5-HT7 receptor Htr7 Antagonist pKi 6.3 501.19 nM Mouse PMID 8394987
    5-HT1F receptor HTR1F Full agonist pKi 6 1,000 nM Human PMID 8380639
    5-HT5A receptor Htr5a Full agonist pKi 5.6 2,512 nM Mouse PMID 8450829
    5-HT1B receptor HTR1B Full agonist pKi — — Human —
    5-HT1D receptor HTR1D Full agonist pKi — — Human —
    5-HT2C receptor HTR2C Full agonist pKi — — Human —
    5-HT7 receptor Htr7 Full agonist pKi — — Rat PMID 8394362
    5-ht1e receptor HTR1E Full agonist pKi — — Human —

    Reading this. pKi, pEC50 and pIC50 are negative log molar values, so a higher number means a tighter interaction; the concentration column converts them for you. Values from non-human species are laboratory measurements and do not translate directly to human effect. Receptor affinity is not a dose — it describes what a molecule binds, not how much of it is safe to take.

    Receptor data from the IUPHAR/BPS Guide to PHARMACOLOGY (v2026.2), licensed CC BY-SA 4.0. Matched to this substance by InChIKey.

    Effect Profile

    Curated + 19 Reports
    Stimulant 6.5

    Strong euphoria and anxiety/jitters with moderate focus and stimulation

    Stimulation / Energy×3
    6
    Euphoria / Mood Lift×2
    10
    Focus / Productivity×2
    7
    Anxiety / Jitters×1
    10

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1d Half tolerance 10d Baseline ~18d

    Experience Report Analysis

    Erowid
    19 Reports
    1999–2008 Date Range
    12 Effects Detected

    Demographics

    Gender Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 19 experience reports (19 Erowid)

    19 Reports
    12 Effects Detected
    6 Positive
    4 Adverse
    2 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 6

    Stimulation 57.9% 70%
    Empathy 52.6% 70%
    Euphoria 47.4% 70%
    Music Enhancement 36.8% 70%
    Color Enhancement 26.3% 70%
    Tactile Enhancement 26.3% 70%

    Adverse Effects 4

    Jaw Clenching 36.8% 70%
    Anxiety 31.6% 70%
    Headache 31.6% 70%
    Nausea 26.3% 70%

    Dosage Distribution

    Dose distribution from experience reports

    Median: 75.0 mg IQR: 50.0–100.0 mg n=11

    Common Combinations

    Most co-occurring substances in experience reports

    Form / Preparation

    Most common forms and preparations reported

    Body-Weight Dosing

    Dose relative to body weight from reports with weight data

    Median: 0.973 mg/kg IQR: 0.735–1.073 mg/kg n=10

    Redose Patterns

    Redosing behavior across 13 reports

    30.8% Redosed
    1.3 Avg Doses
    ← Back to Tfmpp